An international clinical trial found that new drug aficamten boosts exercise capacity and quality of life for obstructive hypertrophic cardiomyopathy patients.
Aficamten Showcases oHCM Benefit in Phase 3 SEQUOIA-HCM Trial hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.
New Cardiomyopathy Guidelines Endorse Cardiac Myosin Inhibitors, Expanded Role for Exercise hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.
Telemedicine delivers the same level of care as in-person, satisfies patients and physicians and drives down healthcare costs, cardiologist Steve Ommen says.